Credit Suisse Group set a $152.00 price objective on Incyte Corporation (NASDAQ:INCY) in a research report sent to investors on Sunday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts have also recently weighed in on the company. BidaskClub cut Incyte Corporation from a buy rating to a hold rating in a research report on Thursday, July 6th. Jefferies Group LLC restated a buy rating and issued a $165.00 price target on shares of Incyte Corporation in a research report on Tuesday, July 4th. Barclays PLC raised their price target on Incyte Corporation from $135.00 to $185.00 and gave the company an overweight rating in a research report on Tuesday, July 4th. Cowen and Company restated an outperform rating and issued a $130.00 price target on shares of Incyte Corporation in a research report on Monday, July 3rd. Finally, Gabelli restated a buy rating and issued a $174.00 price target on shares of Incyte Corporation in a research report on Wednesday, June 28th. Seven research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Buy and an average price target of $141.80.

Shares of Incyte Corporation (NASDAQ INCY) opened at 130.45 on Friday. The stock’s market cap is $26.71 billion. The stock’s 50 day moving average is $127.46 and its 200-day moving average is $127.57. Incyte Corporation has a 12-month low of $75.52 and a 12-month high of $153.15.

Incyte Corporation (NASDAQ:INCY) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. Incyte Corporation had a negative return on equity of 20.09% and a negative net margin of 8.72%. The business had revenue of $384.08 million during the quarter, compared to analysts’ expectations of $359.19 million. During the same quarter last year, the business posted $0.12 earnings per share. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. Equities analysts anticipate that Incyte Corporation will post ($0.74) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/incyte-corporation-incy-pt-set-at-152-00-by-credit-suisse-group/1453710.html.

In related news, Director Jean Jacques Bienaime purchased 500 shares of Incyte Corporation stock in a transaction that occurred on Monday, May 15th. The shares were purchased at an average cost of $115.00 per share, with a total value of $57,500.00. Following the transaction, the director now owns 4,177 shares of the company’s stock, valued at approximately $480,355. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Paul Trower sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $126.18, for a total value of $378,540.00. Following the transaction, the insider now directly owns 12,148 shares in the company, valued at $1,532,834.64. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 1,500 shares of company stock worth $185,530 and have sold 47,275 shares worth $5,758,636. Insiders own 13.70% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the company. Highland Capital Management LLC bought a new position in Incyte Corporation during the second quarter valued at approximately $508,000. Sit Investment Associates Inc. increased its stake in Incyte Corporation by 35.4% in the second quarter. Sit Investment Associates Inc. now owns 40,650 shares of the biopharmaceutical company’s stock valued at $5,118,000 after buying an additional 10,630 shares in the last quarter. Exane Asset Management acquired a new stake in Incyte Corporation during the second quarter valued at about $126,000. Aperio Group LLC increased its stake in Incyte Corporation by 11.4% in the second quarter. Aperio Group LLC now owns 52,330 shares of the biopharmaceutical company’s stock valued at $6,589,000 after buying an additional 5,335 shares in the last quarter. Finally, LS Investment Advisors LLC increased its stake in Incyte Corporation by 12.9% in the second quarter. LS Investment Advisors LLC now owns 5,595 shares of the biopharmaceutical company’s stock valued at $704,000 after buying an additional 641 shares in the last quarter. 92.35% of the stock is currently owned by hedge funds and other institutional investors.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.